恒瑞医药：HRS-3095片获准开展临床试验

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-3095 tablets, a self-developed small molecule compound targeting immune cells for allergic diseases [1] Group 1: Product Development - HRS-3095 tablets are designed to treat allergic diseases and have shown promising results in preclinical studies, effectively improving skin allergy symptoms in mice [1] - The total research and development investment for the HRS-3095 project has reached approximately 16.03 million yuan [1] Group 2: Market Position - Currently, there are no approved drugs targeting the same mechanism for the CSU indication in both domestic and international markets [1]